

Tjalf Ziemssen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1820711/tjalf-ziemssen-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

356
papers

8,226
citations

47
h-index

75
g-index

416
ext. papers

10,183
ext. citations

4.9
avg, IF

6.57
L-index

#	Paper	IF	Citations
356	The need for a strategic therapeutic approach: multiple sclerosis in check.. <i>Therapeutic Advances in Chronic Disease</i> , 2022 , 13, 20406223211063032	4.9	4
355	Serum neurofilament indicates that DBS surgery can cause neuronal damage whereas stimulation itself does not.. <i>Scientific Reports</i> , 2022 , 12, 1446	4.9	1
354	Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany.. <i>Journal of Neurology</i> , 2022 , 1	5.5	3
353	Time-On-Task Effects on Working Memory Gating Processes-A Role of Theta Synchronization and the Norepinephrine System.. <i>Cerebral Cortex Communications</i> , 2022 , 3, tgac001	1.9	0
352	Serum Neurofilament Light Chain as a Biomarker of Brain Injury in Wilson's Disease: Clinical and Neuroradiological Correlations.. <i>Movement Disorders</i> , 2022 ,	7	2
351	Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585211061343	5	2
350	A role of the norepinephrine system or effort in the interplay of different facets of inhibitory control.. <i>Neuropsychologia</i> , 2022 , 166, 108143	3.2	0
349	Neural and glial damage markers in women after long-term weight-recovery from anorexia nervosa. <i>Psychoneuroendocrinology</i> , 2022 , 135, 105576	5	0
348	Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence analysis from a societal perspective in Germany.. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022 , 6, 205521752211007511	2	0
347	Adherence to Subcutaneous Interferon Beta-1a in Multiple Sclerosis Patients Receiving Periodic Feedback on Drug Use by Discussion of Readouts of Their Rebismart Injector: Results of the Prospective Cohort Study REBIFLECT.. <i>Advances in Therapy</i> , 2022 , 1	4.1	
346	Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety.. <i>Wiener Medizinische Wochenschrift</i> , 2022 , 1	2.9	1
345	Efficacy of prolonged-release fampridine versus placebo on walking ability, dynamic and static balance, physical impact of multiple sclerosis, and quality of life: an integrated analysis of MOBILE and ENHANCE. <i>Therapeutic Advances in Neurological Disorders</i> , 2022 , 15, 175628642210903	6.6	
344	Transparent Quality Optimization for Machine Learning-Based Regression in Neurology. <i>Journal of Personalized Medicine</i> , 2022 , 12, 908	3.6	
343	Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation. <i>Frontiers in Immunology</i> , 2021 , 12, 715195	8.4	1
342	Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation. <i>Frontiers in Immunology</i> , 2021 , 12, 715195	8.4	0
341	Lymphocyte Counts and Multiple Sclerosis Therapeutics: Between Mechanisms of Action and Treatment-Limiting Side Effects. <i>Cells</i> , 2021 , 10,	7.9	7
340	Digital Biomarkers in Multiple Sclerosis. <i>Brain Sciences</i> , 2021 , 11,	3.4	4

339	Automated Analysis of the Two-Minute Walk Test in Clinical Practice Using Accelerometer Data. <i>Brain Sciences</i> , 2021 , 11,	3.4	1
338	Cladribine Alters Immune Cell Surface Molecules for Adhesion and Costimulation: Further Insights to the Mode of Action in Multiple Sclerosis. <i>Cells</i> , 2021 , 10,	7.9	3
337	Daten sammeln aus der Praxis: der Weg zum digitalen MS-Zwilling. <i>Der Neurologe Und Psychiater</i> , 2021 , 22, 30-36	0	
336	Descriptive Analysis of Real-World Data on Fingolimod Long-Term Treatment of Young Adult RRMS Patients. <i>Frontiers in Neurology</i> , 2021 , 12, 637107	4.1	3
335	B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021 , 8,	9.1	3
334	Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2021 , 12, 650530	4.1	2
333	CSF and Serum Biomarkers of Cerebral Damage in Autoimmune Epilepsy. <i>Frontiers in Neurology</i> , 2021 , 12, 647428	4.1	2
332	Multiple Sclerosis Progression Discussion Tool Usability and Usefulness in Clinical Practice: Cross-sectional, Web-Based Survey. <i>Journal of Medical Internet Research</i> , 2021 , 23, e29558	7.6	1
331	Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: Results from MS PATHS. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021 , 7, 20552173211004634		
330	Digital Twins for Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2021 , 12, 669811	8.4	32
329	Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis. <i>Acta Neuropathologica Communications</i> , 2021 , 9, 81	7.3	4
328	Targeting Lyn Kinase in Chorea-Acanthocytosis: A Translational Treatment Approach in a Rare Disease. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	3
327	CNS inflammation after natalizumab therapy for multiple sclerosis: A retrospective histopathological and CSF cohort study. <i>Brain Pathology</i> , 2021 , 31, e12969	6	5
326	Approach to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2021 , 12, 701752	8.4	8
325	Improving Digital Patient Care: Lessons Learned from Patient-Reported and Expert-Reported Experience Measures for the Clinical Practice of Multidimensional Walking Assessment. <i>Brain Sciences</i> , 2021 , 11,	3.4	3
324	Kommentar der Multiple Sklerose Therapie Konsensus Gruppe (MSTKG) zur S2k-Leitlinie Multiple Sklerose. <i>DGNeurologie</i> , 2021 , 4, 319-326	0.2	0
323	The Change of Fingolimod Patient Profiles over Time: A Descriptive Analysis of Two Non-Interventional Studies PANGAEA and PANGAEA 2.0. <i>Journal of Personalized Medicine</i> , 2021 , 11,	3.6	2
322	How to reduce the delay of diagnosing secondary progression in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 646-647	5	1

321	Comparative study of microvascular function: Forearm blood flow versus dynamic retinal vessel analysis. <i>Clinical Physiology and Functional Imaging</i> , 2021 , 41, 42-50	2.4	
320	Dissonance in Music Impairs Spatial Gait Parameters in Patients with Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2021 , 11, 363-372	5.3	0
319	Fear of falling and falls in people with multiple sclerosis: A literature review. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 47, 102609	4	4
318	A focus on secondary progressive multiple sclerosis (SPMS): challenges in diagnosis and definition. <i>Journal of Neurology</i> , 2021 , 268, 1210-1221	5.5	40
317	Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper). <i>Therapeutic Advances in Neurological Disorders</i> , 2021 , 14, 17562864211039648	6.6	13
316	Relation of retinal and hippocampal thickness in patients with amnesic mild cognitive impairment and healthy controls. <i>Brain and Behavior</i> , 2021 , 11, e02035	3.4	1
315	Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial. <i>Therapeutic Advances in Neurological Disorders</i> , 2021 , 14, 1756286420982134	6.6	11
314	Impedimetric Microfluidic Sensor-in-a-Tube for Label-Free Immune Cell Analysis. <i>Small</i> , 2021 , 17, e2002549	5.9	9
313	Serum biomarkers of cerebral cellular stress after self-limiting tonic clonic seizures: An exploratory study. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2021 , 85, 1-5	3.2	7
312	Electronic Health Interventions in the Case of Multiple Sclerosis: From Theory to Practice. <i>Brain Sciences</i> , 2021 , 11,	3.4	11
311	Differential longitudinal changes of neuronal and glial damage markers in anorexia nervosa after partial weight restoration. <i>Translational Psychiatry</i> , 2021 , 11, 86	8.6	3
310	Delayed retinal vein recovery responses indicate both non-adaptation to stress as well as increased risk for stroke: the SABPA study. <i>Cardiovascular Journal of Africa</i> , 2021 , 32, 5-16	0.7	1
309	Predictors of Adherence Among Patients With Multiple Sclerosis Using the BETACONNECT Autoinjector: A Prospective Observational Cohort Study. <i>Frontiers in Neurology</i> , 2021 , 12, 643126	4.1	4
308	Interleukin-17 and Th17 Lymphocytes Directly Impair Motoneuron Survival of Wildtype and FUS-ALS Mutant Human iPSCs. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
307	Alemtuzumab in a Large Real-Life Cohort: Interim Baseline Data of the TREAT-MS Study. <i>Frontiers in Neurology</i> , 2021 , 12, 620758	4.1	0
306	Innovation in Digital Education: Lessons Learned from the Multiple Sclerosis Management Master's Program. <i>Brain Sciences</i> , 2021 , 11,	3.4	1
305	Profiles of eHealth Adoption in Persons with Multiple Sclerosis and Their Caregivers. <i>Brain Sciences</i> , 2021 , 11,	3.4	3
304	Wie messe ich das Unsichtbare?. <i>Der Neurologe Und Psychiater</i> , 2021 , 22, 29-34	0	1

303	Multiple sclerosis therapy consensus group (MSTCG): answers to the discussion questions. <i>Neurological Research and Practice</i> , 2021 , 3, 44	3.2	3
302	CONCERTO: A randomized, placebo-controlled trial of oral laquinimod in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211032803	5	3
301	Using Machine Learning Algorithms for Identifying Gait Parameters Suitable to Evaluate Subtle Changes in Gait in People with Multiple Sclerosis. <i>Brain Sciences</i> , 2021 , 11,	3.4	4
300	Cost of illness in multiple sclerosis by disease characteristics - A review of reviews. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021 , 1-19	2.2	2
299	Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children. <i>Annals of Clinical and Translational Neurology</i> , 2021 , 8, 2013-2024	5.3	1
298	Serum neurofilament light chain levels are associated with stroke severity and functional outcome in patients undergoing endovascular therapy for large vessel occlusion. <i>Journal of the Neurological Sciences</i> , 2021 , 429, 118063	3.2	0
297	Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study. <i>Therapeutic Advances in Neurological Disorders</i> , 2021 , 14, 1756286421993999	6.6	4
296	The Multiple Sclerosis Data Alliance Catalogue: Enabling Web-Based Discovery of Metadata from Real-World Multiple Sclerosis Data Sources.. <i>International Journal of MS Care</i> , 2021 , 23, 261-268	2.3	2
295	Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data. <i>Multiple Sclerosis Journal</i> , 2021 , 13524585211061335	5.5	1
294	Serum Neurofilament Light Chain: A Marker of Nervous System Damage in Myopathies.. <i>Frontiers in Neuroscience</i> , 2021 , 15, 791670	5.1	1
293	Evozierte Potenziale - noch up to date?. <i>Der Neurologe Und Psychiater</i> , 2020 , 21, 28-34	0	1
292	On the Reliability of Examining Dual-Tasking Abilities Using a Novel E-Health Device-A Proof of Concept Study in Multiple Sclerosis. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	1
291	Der Patient als Experte. <i>Der Neurologe Und Psychiater</i> , 2020 , 21, 33-36	0	1
290	Real-World Evidence on the Societal Economic Relapse Costs in Patients with Multiple Sclerosis. <i>Pharmacoeconomics</i> , 2020 , 38, 883-892	4.4	6
289	Visual Feedback and Postural Control in Multiple Sclerosis. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	6
288	Fingolimod Leads to Immediate Immunological Changes Within 6 h After First Administration. <i>Frontiers in Neurology</i> , 2020 , 11, 391	4.1	5
287	Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies. <i>Neurology and Therapy</i> , 2020 , 9, 443-457	4.6	4
286	Data Collection in Multiple Sclerosis: The MSDS Approach. <i>Frontiers in Neurology</i> , 2020 , 11, 445	4.1	12

285	Health-Related Quality of Life and the Relationship to Treatment Satisfaction in Patients with Multiple Sclerosis: Insights from a Large Observational Study. <i>Patient Preference and Adherence</i> , 2020 , 14, 869-880	2.4	7
284	A Digital Patient Portal for Patients With Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2020 , 11, 400	4.1	13
283	Clinical outcome measures in multiple sclerosis: A review. <i>Autoimmunity Reviews</i> , 2020 , 19, 102512	13.6	47
282	Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts - the CONFIDENCE study protocol. <i>BMC Neurology</i> , 2020 , 20, 95	3.1	10
281	Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis. <i>Scientific Reports</i> , 2020 , 10, 5941	4.9	24
280	Balance Testing in Multiple Sclerosis-Improving Neurological Assessment With Static Posturography?. <i>Frontiers in Neurology</i> , 2020 , 11, 135	4.1	10
279	Properties of lower level processing modulate the actions of the norepinephrine system during response inhibition. <i>Biological Psychology</i> , 2020 , 152, 107862	3.2	1
278	Event-Driven Immunoprofiling Predicts Return of Disease Activity in Alemtuzumab-Treated Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2020 , 11, 56	8.4	16
277	How to Implement Adherence-Promoting Programs in Clinical Practice? A Discrete Choice Experiment on Physicians' Preferences. <i>Patient Preference and Adherence</i> , 2020 , 14, 267-276	2.4	3
276	Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study. <i>CNS Drugs</i> , 2020 , 34, 185-196	6.7	32
275	Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020 , 6, 2055217320972137	2	2
274	A Physician-Completed Digital Tool for Evaluating Disease Progression (Multiple Sclerosis Progression Discussion Tool): Validation Study. <i>Journal of Medical Internet Research</i> , 2020 , 22, e16932	7.6	20
273	A Novel, Integrative Approach for Evaluating Progression in Multiple Sclerosis: Development of a Scoring Algorithm. <i>JMIR Medical Informatics</i> , 2020 , 8, e17592	3.6	4
272	The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study. <i>Journal of Medical Internet Research</i> , 2020 , 22, e17921	7.6	12
271	Gaining First Insights on Secondary Progressive Multiple Sclerosis Patients Treated With Siponimod in Clinical Routine: Protocol of the Noninterventional Study AMASIA. <i>JMIR Research Protocols</i> , 2020 , 9, e19598	2	9
270	Peripheral nerve field stimulation in medically refractory trigeminal neuralgia attributed to multiple sclerosis. <i>Journal of Neurosurgery</i> , 2020 , 134, 1244-1250	3.2	2
269	Neurofilament light chain in serum is significantly increased in chorea-acanthocytosis. <i>Parkinsonism and Related Disorders</i> , 2020 , 80, 28-31	3.6	5
268	Pneumocystis pneumonia in a patient treated with alemtuzumab for relapsing multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 38, 101503	4	5

267	Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1729-1739	5	22
266	Efficacy of alemtuzumab over 6 years in relapsing-remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1719-1728	5	8
265	Differentiating societal costs of disability worsening in multiple sclerosis. <i>Journal of Neurology</i> , 2020 , 267, 1035-1042	5.5	16
264	Antigen-shift in varicella-zoster virus-specific T-cell immunity over the course of Fingolimod-treatment in relapse-remitting multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 38, 101859	4	6
263	A mixed methods approach towards understanding key disease characteristics associated with the progression from RRMS to SPMS: Physicians and patients' views. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 38, 101861	4	12
262	Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 1866-1876	5	12
261	The role of TH17 cells in multiple sclerosis: Therapeutic implications. <i>Autoimmunity Reviews</i> , 2020 , 19, 102647	13.6	57
260	The transitional phase of multiple sclerosis: The concept of PANGAEA 2.0 evolution study. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 46, 102523	4	2
259	Patient- versus physician-reported relapses in multiple sclerosis: insights from a large observational study. <i>European Journal of Neurology</i> , 2020 , 27, 2531-2538	6	8
258	The Dresden Protocol for Multidimensional Walking Assessment (DMWA) in Clinical Practice. <i>Frontiers in Neuroscience</i> , 2020 , 14, 582046	5.1	8
257	Harnessing Real-World Data to Inform Decision-Making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS). <i>Frontiers in Neurology</i> , 2020 , 11, 632	4.1	23
256	A Comprehensive Monitoring Study on Electrocardiographic Assessments and Cardiac Events After Fingolimod First Dose-Possible Predictors of Cardiac Outcomes. <i>Frontiers in Neurology</i> , 2020 , 11, 818	4.1	5
255	Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study. <i>CNS Drugs</i> , 2020 , 34, 973-988	6.7	19
254	No Impact of Long-Term Fingolimod Treatment on Fecal Secretory Immunoglobulin A Levels in Patients With Multiple Sclerosis. <i>Frontiers in Cell and Developmental Biology</i> , 2020 , 8, 567659	5.7	0
253	Why Cognitive-Cognitive Dual-Task Testing Assessment Should Be Implemented in Studies on Multiple Sclerosis and in Regular Clinical Practice. <i>Frontiers in Neurology</i> , 2020 , 11, 905	4.1	1
252	Autoantibodies against central nervous system antigens in a subset of B cell-dominant multiple sclerosis patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 21512-21518	11.5	12
251	Gender disparities in health resource utilization in patients with relapsing-remitting multiple sclerosis: a prospective longitudinal real-world study with more than 2000 patients. <i>Therapeutic Advances in Neurological Disorders</i> , 2020 , 13, 1756286420960274	6.6	4
250	Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 48-56	5	30

249	Response to Hyun J.W. et al. "Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis". <i>Multiple Sclerosis Journal</i> , 2020 , 26, 742-743	5	1
248	Letter to the editor regarding "Therapeutic drug monitoring of natalizumab". <i>Multiple Sclerosis Journal</i> , 2020 , 26, 741-742	5	
247	Internationale Brain Health Initiative und Multiple Sklerose. <i>DGNeurologie</i> , 2020 , 3, 107-115	0.2	2
246	A possible role of the norepinephrine system during sequential cognitive flexibility - Evidence from EEG and pupil diameter data. <i>Cortex</i> , 2020 , 128, 22-34	3.8	1
245	Should We Use Clinical Tools to Identify Disease Progression?. <i>Frontiers in Neurology</i> , 2020 , 11, 628542	4.1	6
244	Long-term peripheral immune cell profiling reveals further targets of oral cladribine in MS. <i>Annals of Clinical and Translational Neurology</i> , 2020 , 7, 2199-2212	5.3	22
243	Dem MS-Phänotyp auf der Spur. <i>Der Neurologe Und Psychiater</i> , 2019 , 20, 33-36	0	2
242	Clinical relevance of circadian melatonin release in relapsing-remitting multiple sclerosis. <i>Journal of Molecular Medicine</i> , 2019 , 97, 1547-1555	5.5	6
241	Anodal tDCS affects neuromodulatory effects of the norepinephrine system on superior frontal theta activity during response inhibition. <i>Brain Structure and Function</i> , 2019 , 224, 1291-1300	4	22
240	Tetrahydrocannabinol: cannabidiol oromucosal spray for treating symptoms of multiple sclerosis spasticity: newest evidence. <i>Neurodegenerative Disease Management</i> , 2019 , 9, 1-2	2.8	1
239	Review: Patient-reported outcomes in multiple sclerosis care. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 33, 61-66	4	47
238	How the depth of processing modulates emotional interference - evidence from EEG and pupil diameter data. <i>Cognitive, Affective and Behavioral Neuroscience</i> , 2019 , 19, 1231-1246	3.5	6
237	Response to: Kobayashi et al.: "Erythroblast appearance associated with natalizumab" Multiple Sclerosis and Related Disorders 2019. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 32, 114-115	4	1
236	Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019 , 6, e555	9.1	63
235	Nonwalking response to fampridine in patients with multiple sclerosis in a real-world setting. <i>Therapeutic Advances in Chronic Disease</i> , 2019 , 10, 2040622319835136	4.9	7
234	Daily Practice Managing Resistant Multiple Sclerosis Spasticity With Delta-9-Tetrahydrocannabinol: Cannabidiol Oromucosal Spray: A Systematic Review of Observational Studies. <i>Journal of Central Nervous System Disease</i> , 2019 , 11, 1179573519831997	4.4	12
233	On the interrelation of 1/ neural noise and norepinephrine system activity during motor response inhibition. <i>Journal of Neurophysiology</i> , 2019 , 121, 1633-1643	3.2	17
232	The Investigation of the Cardiovascular and Sudomotor Autonomic Nervous System-A Review. <i>Frontiers in Neurology</i> , 2019 , 10, 53	4.1	47

231	Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings. <i>Frontiers in Neurology</i> , 2019 , 10, 253	4.1	12
230	Real-world persistence and benefit-risk profile of fingolimod over 36 months in Germany. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019 , 6, e548	9.1	24
229	Autonome Small-Fiber-Neuropathien. <i>Neurologie Up2date</i> , 2019 , 2, 51-65	0.1	1
228	Spectral Analysis of Heart Rate Variability: Time Window Matters. <i>Frontiers in Neurology</i> , 2019 , 10, 545	4.1	53
227	Early central vs. peripheral immunological and neurobiological effects of fingolimod-a longitudinal study. <i>Journal of Molecular Medicine</i> , 2019 , 97, 1263-1271	5.5	7
226	Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumab. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 39, 101893	4	7
225	Kipptischuntersuchung Schritt für Schritt. <i>Neurologie Up2date</i> , 2019 , 2, 339-346	0.1	1
224	Reasons to switch: a noninterventional study evaluating immunotherapy switches in a large German multicentre cohort of patients with relapsing-remitting multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2019 , 12, 1756286419892077	6.6	6
223	Molecular biomarkers in multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2019 , 16, 272	10.1	75
222	Mutually reinforcing effects of genetic variants and interferon- β a therapy for pulmonary arterial hypertension development in multiple sclerosis patients. <i>Pulmonary Circulation</i> , 2019 , 9, 2045894019872192	2.7	4
221	Metabolic and Non-Metabolic Peripheral Neuropathy: Is there a Place for Therapeutic Apheresis?. <i>Hormone and Metabolic Research</i> , 2019 , 51, 779-784	3.1	4
220	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 175-187	27.4	172
219	How minimal variations in neuronal cytoskeletal integrity modulate cognitive control. <i>NeuroImage</i> , 2019 , 185, 129-139	7.9	17
218	International consensus on quality standards for brain health-focused care in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1809-1818	5	31
217	Multiple sclerosis registries in Europe - An updated mapping survey. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 27, 171-178	4	33
216	Exploring individual multiple sclerosis lesion volume change over time: Development of an algorithm for the analyses of longitudinal quantitative MRI measures. <i>NeuroImage: Clinical</i> , 2019 , 21, 101623	5.3	8
215	Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine. <i>CNS Drugs</i> , 2019 , 33, 61-79	6.7	20
214	Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology. <i>Journal of Autoimmunity</i> , 2018 , 90, 116-131	15.5	32

213	Patient satisfaction and healthcare services in specialized multiple sclerosis centres in Germany. <i>Therapeutic Advances in Neurological Disorders</i> , 2018 , 11, 1756285617748845	6.6	8
212	Improving multiple sclerosis management and collecting safety information in the real world: the MSDS3D software approach. <i>Expert Opinion on Drug Safety</i> , 2018 , 17, 369-378	4.1	20
211	Determination of Seminal Concentration of Fingolimod and Fingolimod-Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod. <i>Clinical Pharmacology in Drug Development</i> , 2018 , 7, 217-221	2.3	2
210	Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit-Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA. <i>Neurotherapeutics</i> , 2018 , 15, 190-199	6.4	11
209	Comment on Y.D. Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" Multiple Sclerosis and Related Disorders 2017. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 22, 68-69	4	1
208	Letter to the editor to the paper: "Acute and long-term effects of fingolimod on heart rhythm and heart rate variability in patients with multiple sclerosis". <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 22, 57-58	4	
207	Rescue therapy with alemtuzumab in B cell/antibody-mediated multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2018 , 11, 1756286418759895	6.6	1
206	Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. <i>Lancet Neurology</i> , 2018 , 17, 405-415	24.1	150
205	The role of phasic norepinephrine modulations during task switching: evidence for specific effects in parietal areas. <i>Brain Structure and Function</i> , 2018 , 223, 925-940	4	26
204	Natalizumab during pregnancy and lactation. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1627-1634	5	34
203	An Innovative Technique to Assess Spontaneous Baroreflex Sensitivity with Short Data Segments: Multiple Trigonometric Regressive Spectral Analysis. <i>Frontiers in Physiology</i> , 2018 , 9, 10	4.6	6
202	Dual-Tasking in Multiple Sclerosis - Implications for a Cognitive Screening Instrument. <i>Frontiers in Human Neuroscience</i> , 2018 , 12, 24	3.3	9
201	Multi-component relaxation in clinically isolated syndrome: Lesion myelination may predict multiple sclerosis conversion. <i>NeuroImage: Clinical</i> , 2018 , 20, 61-70	5.3	8
200	Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1337-1346	5	15
199	MS-Dokumentation, -Register und -Management 2018 , 435-447		
198	Perceptions on the value of bodily functions in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2018 , 137, 356-362	3.8	54
197	Letter to the editor on the paper: "The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing". <i>Multiple Sclerosis Journal</i> , 2018 , 24, 820-822	5	1
196	Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up. <i>Frontiers in Neurology</i> , 2018 , 9, 1071	4.1	23

195	Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients. <i>Frontiers in Immunology</i> , 2018 , 9, 2669	8.4	23
194	Reader response: Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks. <i>Neurology</i> , 2018 , 91, 849-850	6.5	
193	Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential. <i>CNS Drugs</i> , 2018 , 32, 1159-1171	6.7	28
192	Wissensstand von Patienten und Gesundheitsberufen über Diabetes-bedingte Augenerkrankungen (Risikofaktoren, Früherkennung und Behandlung). <i>Diabetologie Und Stoffwechsel</i> , 2018 , 13, 263-269	0.7	0
191	Sudomotor Testing of Diabetes Polyneuropathy. <i>Frontiers in Neurology</i> , 2018 , 9, 803	4.1	23
190	Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting. <i>Therapeutic Advances in Neurological Disorders</i> , 2018 , 11, 1756286418803248	6.6	11
189	Predictors of response to opicinumab in acute optic neuritis. <i>Annals of Clinical and Translational Neurology</i> , 2018 , 5, 1154-1162	5.3	15
188	The norepinephrine system shows information-content specific properties during cognitive control - Evidence from EEG and pupillary responses. <i>NeuroImage</i> , 2017 , 149, 44-52	7.9	85
187	Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study. <i>BMC Neurology</i> , 2017 , 17, 11	3.1	21
186	Multiple sclerosis in the real world: A systematic review of fingolimod as a case study. <i>Autoimmunity Reviews</i> , 2017 , 16, 355-376	13.6	46
185	Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation. <i>Journal of Neuroinflammation</i> , 2017 , 14, 41	10.1	36
184	Adrenal medullary dysfunction as a feature of obesity. <i>International Journal of Obesity</i> , 2017 , 41, 714-721	5.5	15
183	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. <i>Lancet Neurology</i> , 2017 , 16, 271-281	24.1	101
182	Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , 2017 , 16, 189-199	24.1	156
181	A self-sustained loop of inflammation-driven inhibition of beige adipogenesis in obesity. <i>Nature Immunology</i> , 2017 , 18, 654-664	19.1	104
180	Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL. <i>PLoS ONE</i> , 2017 , 12, e0173353	3.7	13
179	Patients' preferences for involvement in the decision-making process for treating diabetic retinopathy. <i>BMC Ophthalmology</i> , 2017 , 17, 139	2.3	16
178	Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS. <i>Journal of Neuroinflammation</i> , 2017 , 14, 172	10.1	12

177	Fatigue and Sleep in Multiple Sclerosis Patients: A Comparison of Self-Report and Performance-Based Measures. <i>Frontiers in Neurology</i> , 2017 , 8, 703	4.1	5
176	Induction therapy for the management of early relapsing forms of multiple sclerosis. A critical opinion. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 1553-1556	4	6
175	Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 1649-1660	4	33
174	Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world. <i>Therapeutic Advances in Neurological Disorders</i> , 2017 , 10, 343-359	6.6	69
173	Subthalamic nucleus stimulation and levodopa modulate cardiovascular autonomic function in Parkinson disease. <i>Scientific Reports</i> , 2017 , 7, 7012	4.9	1
172	Demands on response inhibition processes determine modulations of theta band activity in superior frontal areas and correlations with pupillometry - Implications for the norepinephrine system during inhibitory control. <i>NeuroImage</i> , 2017 , 157, 575-585	7.9	50
171	Healthcare resource use and costs of multiple sclerosis patients in Germany before and during fampridine treatment. <i>BMC Neurology</i> , 2017 , 17, 62	3.1	4
170	The norepinephrine system affects specific neurophysiological subprocesses in the modulation of inhibitory control by working memory demands. <i>Human Brain Mapping</i> , 2017 , 38, 68-81	5.9	53
169	ActiGait implantable drop foot stimulator in multiple sclerosis: a new indication. <i>Journal of Neurosurgery</i> , 2017 , 126, 1685-1690	3.2	9
168	The norepinephrine system and its relevance for multi-component behavior. <i>NeuroImage</i> , 2017 , 146, 1062-1070	7.9	36
167	Umsetzung der Nationalen VersorgungsLeitlinie (NVL) zur Therapie des Diabetes mellitus Typ 2 in diabetologischen Schwerpunktpraxen. <i>Diabetes Aktuell</i> , 2017 , 15, 257-270	0	0
166	Autonomic Dysfunction in Wilson Disease: A Comprehensive Evaluation during a 3-Year Follow Up. <i>Frontiers in Physiology</i> , 2017 , 8, 778	4.6	10
165	Cutaneous Autonomic Pilocomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinson Disease (CAPTURE PD): Protocol for a Multicenter Study. <i>Frontiers in Neurology</i> , 2017 , 8, 212	4.1	12
164	Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis. <i>Frontiers in Neuroscience</i> , 2017 , 11, 540	5.1	11
163	Response to: S. Segal-Jazbec et al.: "Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis" <i>Multiple Sclerosis and Related Disorders</i> 2017 . <i>Multiple Sclerosis and Related Disorders</i> , 2017 , 17, 177-178	4	1
162	Long-term safety and tolerability of glatiramer acetate 20 mg/ml in the treatment of relapsing forms of multiple sclerosis. <i>Expert Opinion on Drug Safety</i> , 2017 , 16, 247-255	4.1	19
161	Limited Time from the Diabetes Patients Perspective: Need for Conversation with the Eye Specialist. <i>Ophthalmologica</i> , 2016 , 236, 154-158	3.7	
160	Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab. <i>BMC Neurology</i> , 2016 , 16, 98	3.1	9

159	Immunomodulatory treatments and cognition in MS. <i>Acta Neurologica Scandinavica</i> , 2016 , 134 Suppl 200, 55-9	3.8	12
158	Development of the multiple sclerosis (MS) early mobility impairment questionnaire (EMIQ). <i>Journal of Neurology</i> , 2016 , 263, 1969-83	5.5	14
157	Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach. <i>BMC Neurology</i> , 2016 , 16, 124	3.1	55
156	New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies. <i>Journal of Neuroinflammation</i> , 2016 , 13, 164	10.1	32
155	Therapy satisfaction and adherence in patients with relapsing-remitting multiple sclerosis: the THEPA-MS survey. <i>Therapeutic Advances in Neurological Disorders</i> , 2016 , 9, 250-63	6.6	40
154	Acute effects of alemtuzumab infusion in patients with active relapsing-remitting MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016 , 3, e228	9.1	58
153	Effector T-cell trafficking between the leptomeninges and the cerebrospinal fluid. <i>Nature</i> , 2016 , 530, 349-53	50.4	203
152	QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients. <i>Journal of Neurology</i> , 2016 , 263, 784-91	5.5	13
151	Optimizing treatment success in multiple sclerosis. <i>Journal of Neurology</i> , 2016 , 263, 1053-65	5.5	111
150	Designing an Electronic Patient Management System for Multiple Sclerosis: Building a Next Generation Multiple Sclerosis Documentation System. <i>Interactive Journal of Medical Research</i> , 2016 , 5, e2	2.1	29
149	Multiple Sclerosis Therapy With Disease-Modifying Treatments in Germany: The PEARL (ProspEctive phArmacoeconomic cohORt evaluation) Noninterventional Study Protocol. <i>JMIR Research Protocols</i> , 2016 , 5, e23	2	9
148	Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study. <i>JAMA Neurology</i> , 2016 , 73, 1089-98	17.2	67
147	6-sulpho LacNAC(+) dendritic cells accumulate in various inflammatory, but not ischaemic conditions of the central nervous system. <i>Neuropathology and Applied Neurobiology</i> , 2016 , 42, 394-8	5.2	4
146	Rationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS). <i>BMC Neurology</i> , 2016 , 16, 109	3.1	17
145	Hands on Alemtuzumab-experience from clinical practice: whom and how to treat. <i>Multiple Sclerosis and Demyelinating Disorders</i> , 2016 , 1,	0	19
144	Hes3 expression in the adult mouse brain is regulated during demyelination and remyelination. <i>Brain Research</i> , 2016 , 1642, 124-130	3.7	6
143	Comparison of baroreflex sensitivity estimated from ECG R-R and inter-systolic intervals obtained by finger plethysmography and radial tonometry. <i>Journal of Neural Transmission</i> , 2016 , 123, 481-90	4.3	3
142	Laquinimod in the treatment of relapsing remitting multiple sclerosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 701-9	5.5	5

141	Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E2973-82	11.5	98
140	Study design of PANGAEA 2.0, a non-interventional study on RRMS patients to be switched to fingolimod. <i>BMC Neurology</i> , 2016 , 16, 129	3.1	19
139	Different responses of the retinal and cutaneous microcirculation to transient dysmetabolic conditions. <i>Atherosclerosis Supplements</i> , 2015 , 18, 1-7	1.7	6
138	Immunoabsorption with regenerating systems in neurological disorders --A single center experience. <i>Atherosclerosis Supplements</i> , 2015 , 18, 119-23	1.7	10
137	Attenuated brain-derived neurotrophic factor and hypertrophic remodelling: the SABPA study. <i>Journal of Human Hypertension</i> , 2015 , 29, 33-9	2.6	11
136	Optimizing therapy early in multiple sclerosis: An evidence-based view. <i>Multiple Sclerosis and Related Disorders</i> , 2015 , 4, 460-469	4	77
135	Acute hyperlipidemia but not hyperhomocysteinemia impairs reflex regulation of the cardiovascular system. <i>Atherosclerosis Supplements</i> , 2015 , 18, 8-15	1.7	9
134	Recognition and treatment of autonomic disturbances in Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2015 , 15, 1189-203	4.3	20
133	The PANGAEA study design - a prospective, multicenter, non-interventional, long-term study on fingolimod for the treatment of multiple sclerosis in daily practice. <i>BMC Neurology</i> , 2015 , 15, 93	3.1	44
132	Effects of the PPAR α agonist pioglitazone on coronary atherosclerotic plaque composition and plaque progression in non-diabetic patients: a double-center, randomized controlled VH-IVUS pilot-trial. <i>Heart and Vessels</i> , 2015 , 30, 286-95	2.1	9
131	Developmental endothelial locus-1 is a homeostatic factor in the central nervous system limiting neuroinflammation and demyelination. <i>Molecular Psychiatry</i> , 2015 , 20, 880-888	15.1	48
130	Time- and frequency-domain parameters of heart rate variability and sympathetic skin response in Parkinson's disease. <i>Journal of Neural Transmission</i> , 2015 , 122, 419-25	4.3	37
129	Development of A Screening Tool to Support Identification of Patients With Secondary Progressive Multiple Sclerosis (Spms). <i>Value in Health</i> , 2015 , 18, A763	3.3	5
128	Ein Jahr Alemtuzumab Was haben wir in der Praxis gelernt? Experten-Erfahrungsaustausch zur Therapie der Multiplen Sklerose. <i>Aktuelle Neurologie</i> , 2015 , 42, 535-541		2
127	PP.41.04. <i>Journal of Hypertension</i> , 2015 , 33, e501	1.9	
126	Pangaea 2.0: State Of The Art Multiple Sclerosis Patient Management In Daily Clinical Practice. A New 3-Year Observational Study Of Patients Receiving Fingolimod. <i>Value in Health</i> , 2015 , 18, A686	3.3	2
125	Confirmed Disability Improvement In Patients With Active Multiple Sclerosis Treated With Fingolimod Versus Brace: A Matched Comparison of Treatments From The Pangaea And Pearl Registry Studies. <i>Value in Health</i> , 2015 , 18, A750	3.3	5
124	Physician-patient communication skills: e-tools. <i>Neurodegenerative Disease Management</i> , 2015 , 5, 51-3	2.8	

123	Sub-analysis of geographical variations in the 2-year observational COPTIMIZE trial of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate. <i>BMC Neurology</i> , 2015 , 15, 189	3.1	6
122	Insulin is a key determinant of elevated retinal arteriolar flicker response in insulin-resistant individuals. <i>Diabetologia</i> , 2015 , 58, 2154-60	10.3	2
121	Dynamic formation of macular microcysts independent of vitreous traction changes. <i>Neurology</i> , 2015 , 84, 436-7	6.5	4
120	36 Months Pangaea: A 5-Year Non-Interventional Study of Safety, Efficacy and Pharmacoeconomic Data for Fingolimod Patients In Daily Clinical Practice. <i>Value in Health</i> , 2015 , 18, A749	3.3	7
119	Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT). <i>Neurology and Therapy</i> , 2015 , 4, 125-36	4.6	22
118	Effects of the Peroxisome Proliferator-Activated Receptor- α Agonist Pioglitazone on Peripheral Vessel Function and Clinical Parameters in Nondiabetic Patients: A Double-Center, Randomized Controlled Pilot Trial. <i>Cardiology</i> , 2015 , 131, 165-71	1.6	2
117	A pragmatic approach to dealing with fingolimod-related lymphopaenia in Europe. <i>Multiple Sclerosis and Related Disorders</i> , 2015 , 4, 83-4	4	4
116	Graves Disease after treatment with alemtuzumab for multiple sclerosis. <i>Hormones</i> , 2015 , 14, 148-53	3.1	15
115	Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic Review. <i>PLoS ONE</i> , 2015 , 10, e0138243	3.7	12
114	Time for Change – Evolution of Real-world Evidence Outcome Measures in Multiple Sclerosis Exemplified by Fingolimod. <i>European Neurological Review</i> , 2015 , 9, 136	0.5	10
113	Local endothelial dysfunction does not affect global endothelial function. <i>Vasa - European Journal of Vascular Medicine</i> , 2015 , 44, 277-84	1.9	1
112	Therapieziele und Therapiemanagement bei schubförmigremittierender Multipler Sklerose. <i>Nervenheilkunde</i> , 2015 , 34, 915-923	0.3	2
111	MS-Dokumentation, MS-Register und MS-Management 2015 , 447-459		
110	Psychometric Analyses to Inform Item Reduction and Evaluate Sensitivity of the Early Mobility Impairment Questionnaire for Multiple Sclerosis. <i>Value in Health</i> , 2014 , 17, A403	3.3	
109	Fingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery disease. <i>BMC Neurology</i> , 2014 , 14, 126	3.1	5
108	Time matters - acute stress response and glucocorticoid sensitivity in early multiple sclerosis. <i>Brain, Behavior, and Immunity</i> , 2014 , 41, 82-9	16.6	11
107	Accumulation and therapeutic modulation of 6-sulfo LacNAc(+) dendritic cells in multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2014 , 1, e33	9.1	25
106	Attenuated NOx responses and myocardial ischemia, a possible risk for structural vascular disease in African men: the SABPA study. <i>Journal of Human Hypertension</i> , 2014 , 28, 438-43	2.6	3

105	Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 851-8	5.5	84
104	Phase 2 BOLD extension study efficacy results for siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2014 , 3, 754-755	4	2
103	Seasonal variation in plasma free normetanephrine concentrations: implications for biochemical diagnosis of pheochromocytoma. <i>European Journal of Endocrinology</i> , 2014 , 170, 349-57	6.5	19
102	A 2-year observational study of patients with relapsing-remitting multiple sclerosis converting to glatiramer acetate from other disease-modifying therapies: the COPTIMIZE trial. <i>Journal of Neurology</i> , 2014 , 261, 2101-11	5.5	28
101	Evidence-based patient information programme in early multiple sclerosis: a randomised controlled trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 411-8	5.5	50
100	Anti-Vascular endothelial growth factor therapy impairs endothelial function of retinal microcirculation in colon cancer patients - an observational study. <i>Experimental & Translational Stroke Medicine</i> , 2013 , 5, 7		13
99	Therapeutic decisions in multiple sclerosis: moving beyond efficacy. <i>JAMA Neurology</i> , 2013 , 70, 1315-24	17.2	67
98	Multiple sclerosis documentation system (MSDS): moving from documentation to management of MS patients. <i>Journal of Neural Transmission</i> , 2013 , 120 Suppl 1, S61-6	4.3	35
97	Perspectives of an innovative ophthalmological technology: optical coherence tomography (OCT)--what should be of interest to the neurologist?. <i>Clinical Neurology and Neurosurgery</i> , 2013 , 115 Suppl 1, S55-9	2	8
96	Defensive coping facilitates higher blood pressure and early sub-clinical structural vascular disease via alterations in heart rate variability: the SABPA study. <i>Atherosclerosis</i> , 2013 , 227, 391-7	3.1	34
95	Management of fingolimod in clinical practice. <i>Clinical Neurology and Neurosurgery</i> , 2013 , 115 Suppl 1, S60-4	2	18
94	Defensive active coping facilitates chronic hyperglycaemia and endothelial dysfunction in African men: the SABPA study. <i>International Journal of Cardiology</i> , 2013 , 168, 999-1005	3.2	4
93	Lipoprotein apheresis of hypercholesterolemic patients mediates vasoprotective gene expression in human endothelial cells. <i>Atherosclerosis Supplements</i> , 2013 , 14, 107-13	1.7	16
92	Regular lipoprotein apheresis maintains residual cardiovascular and microvascular function in patients with advanced atherosclerotic disease. <i>Atherosclerosis Supplements</i> , 2013 , 14, 135-41	1.7	4
91	Nocturnal blood pressure, 3-methoxy-4-hydroxyphenylglycol and carotid intima-media thickness: The SABPA study. <i>Heart Lung and Circulation</i> , 2013 , 22, 917-23	1.8	0
90	Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. <i>Lancet Neurology</i> , 2013 , 12, 756-67	24.1	163
89	Trigonometric regressive spectral analysis: an innovative tool for evaluating the autonomic nervous system. <i>Journal of Neural Transmission</i> , 2013 , 120 Suppl 1, S27-33	4.3	21
88	Metabolomic distinction of microvascular effects of lipoprotein apheresis--a pilot study. <i>Atherosclerosis Supplements</i> , 2013 , 14, 143-9	1.7	5

87	Modern communication technology skills of patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1240-1	5	19
86	Effects of acute and chronic stress on the L-arginine nitric oxide pathway in black and white South Africans: the sympathetic activity and ambulatory blood pressure in Africans study. <i>Psychosomatic Medicine</i> , 2013 , 75, 751-8	3.7	15
85	Employment status in multiple sclerosis: impact of disease-specific and non-disease-specific factors. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1792-9	5	83
84	Neuroborreliosis during natalizumab treatment in multiple sclerosis. <i>Neurology</i> , 2013 , 81, 1012-4	6.5	1
83	Mehr als dokumentieren: computerunterstütztes Patientenmanagement. <i>Der Neurologe Und Psychiater</i> , 2013 , 14, 57-62	0	3
82	Cortisol awakening response is linked to disease course and progression in multiple sclerosis. <i>PLoS ONE</i> , 2013 , 8, e60647	3.7	29
81	The sensory channel of presentation alters subjective ratings and autonomic responses toward disgusting stimuli-Blood pressure, heart rate and skin conductance in response to visual, auditory, haptic and olfactory presented disgusting stimuli. <i>Frontiers in Human Neuroscience</i> , 2013 , 7, 510	3.3	29
80	Die Anwendung von Multi-Touch-Gesten in Patientenmanagementsystemen. <i>Xpert Press</i> , 2013 , 301-315		
79	Static posturography in aging and Parkinson's disease. <i>Frontiers in Aging Neuroscience</i> , 2012 , 4, 20	5.3	31
78	Improving patient-physician dialog: commentary on the results of the MS Choices survey. <i>Patient Preference and Adherence</i> , 2012 , 6, 143-52	2.4	17
77	Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. <i>Movement Disorders</i> , 2012 , 27, 617-26	7	339
76	Autonomic responses to stress in Black versus Caucasian Africans: the SABPA study. <i>Psychophysiology</i> , 2012 , 49, 454-61	4.1	14
75	Modernes Therapiemanagement zur Verbesserung der Therapie mit Interferon β mit MSDS 3D. <i>Aktuelle Neurologie</i> , 2012 , 39, S2-S5		5
74	Neue Perspektiven eines modernen Untersuchungsverfahrens. <i>Der Neurologe Und Psychiater</i> , 2012 , 13, 69-75	0	
73	Psychoneuroimmunology - psyche and autoimmunity. <i>Current Pharmaceutical Design</i> , 2012 , 18, 4485-8	3.3	4
72	Facilitated defensive coping, silent ischaemia and ECG left-ventricular hypertrophy: the SABPA study. <i>Journal of Hypertension</i> , 2012 , 30, 543-50	1.9	36
71	Greater cardiovascular reactivity to a cold stimulus is due to higher cold pain perception in black Africans: the Sympathetic Activity and Ambulatory Blood Pressure in Africans (SABPA) study. <i>Journal of Hypertension</i> , 2012 , 30, 2416-24	1.9	25
70	Wandel in aktueller Bewertung neuer Wirkstoffe erfordert Erhebung pharmakoökonomischer Daten: Behandlungszufriedenheit von Fingolimod (Gilenya) im Vergleich zu Erstlinientherapeutika bei Patienten mit Multipler Sklerose (PANGAEA und PEARL). <i>Aktuelle Neurologie</i> , 2012 , 39, 385-385		5

69	Use and acceptance of electronic communication by patients with multiple sclerosis: a multicenter questionnaire study. <i>Journal of Medical Internet Research</i> , 2012 , 14, e135	7.6	63
68	Cardiovascular autonomic testing in extrapyramidal disorders. <i>Journal of the Neurological Sciences</i> , 2011 , 310, 129-32	3.2	11
67	Symptom management in patients with multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2011 , 311 Suppl 1, S48-52	3.2	42
66	Determination of baroreflex sensitivity during the modified Oxford maneuver by trigonometric regressive spectral analysis. <i>PLoS ONE</i> , 2011 , 6, e18061	3.7	19
65	Functional energetics of CD4 ⁺ -cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders. <i>PLoS ONE</i> , 2011 , 6, e18506	3.7	19
64	Circadian cortisol, depressive symptoms and neurological impairment in early multiple sclerosis. <i>Psychoneuroendocrinology</i> , 2011 , 36, 1505-12	5	29
63	Treatment of dysautonomia in extrapyramidal disorders. <i>Journal of Neurology</i> , 2011 , 258, S339-45	5.5	8
62	Seizures associated with zoledronic acid for osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 1955-9	5.6	20
61	Rapidly progressive course of very late onset multiple sclerosis presenting with Parkinsonism: case report. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 245-9	5	14
60	Baroreceptor sensitivity, cardiovascular responses and ECG left ventricular hypertrophy in men: the SABPA study. <i>Blood Pressure</i> , 2011 , 20, 355-61	1.7	19
59	Trigonometric regressive spectral analysis reliably maps dynamic changes in baroreflex sensitivity and autonomic tone: the effect of gender and age. <i>PLoS ONE</i> , 2010 , 5, e12187	3.7	19
58	Treatment of dysautonomia in extrapyramidal disorders. <i>Therapeutic Advances in Neurological Disorders</i> , 2010 , 3, 53-67	6.6	19
57	CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function. <i>Bone Marrow Transplantation</i> , 2010 , 45, 1489-96	4.4	49
56	Cardiovascular autonomic dysfunction in Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2010 , 289, 74-80	3.2	97
55	LDL apheresis improves deranged cardiovascular modulation in hypercholesterolemic patients. <i>Atherosclerosis</i> , 2010 , 213, 212-7	3.1	9
54	Autonomic function and cerebral autoregulation in patients undergoing carotid endarterectomy. <i>Circulation Journal</i> , 2010 , 74, 2139-45	2.9	23
53	Comprehensive autonomic assessment does not differentiate between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. <i>Journal of Neural Transmission</i> , 2010 , 117, 69-76	4.3	35
52	The cold hand sign in multiple system atrophy: skin perfusion revisited. <i>Journal of Neural Transmission</i> , 2010 , 117, 475-9	4.3	9

51	Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. <i>Annals of Neurology</i> , 2010 , 68, 409-11	9.4	35
50	Baroreflex sensitivity and power spectral analysis during autonomic testing in different extrapyramidal syndromes. <i>Movement Disorders</i> , 2010 , 25, 315-24	7	33
49	Treatment strategies for nonmotor manifestations of Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2009 , 10, 773-84	4	8
48	Education research: cognitive performance is preserved in sleep-deprived neurology residents. <i>Neurology</i> , 2009 , 73, e99-e103	6.5	13
47	Potential side effect of high-dose corticosteroid relapse treatment: acute generalized exanthematous pustulosis (AGEP). <i>Multiple Sclerosis Journal</i> , 2009 , 15, 275-7	5	6
46	Loss of nocturnal blood pressure fall in various extrapyramidal syndromes. <i>Movement Disorders</i> , 2009 , 24, 2136-42	7	76
45	Valsalva manoeuvre in patients with different Parkinsonian disorders. <i>Journal of Neural Transmission</i> , 2009 , 116, 875-80	4.3	36
44	Pupillary responses to intranasal trigeminal and olfactory stimulation. <i>Journal of Neural Transmission</i> , 2009 , 116, 885-9	4.3	12
43	Intensified monitoring of circadian blood pressure and heart rate before and after intravitreal injection of bevacizumab: preliminary findings of a pilot study. <i>International Ophthalmology</i> , 2009 , 29, 213-24	2.2	18
42	Regulation of proteins mediating neurodegeneration in experimental autoimmune encephalomyelitis and multiple sclerosis. <i>Proteomics - Clinical Applications</i> , 2009 , 3, 1273-87	3.1	19
41	Ethnic-specific correlations of visfatin with circulating markers of endothelial inflammation and function. <i>Obesity</i> , 2009 , 17, 2210-5	8	5
40	Neurological disability, psychological distress, and health-related quality of life in MS patients within the first three years after diagnosis. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 752-8	5	49
39	Multiple sclerosis beyond EDSS: depression and fatigue. <i>Journal of the Neurological Sciences</i> , 2009 , 277 Suppl 1, S37-41	3.2	109
38	Effect of BEMER magnetic field therapy on the level of fatigue in patients with multiple sclerosis: a randomized, double-blind controlled trial. <i>Journal of Alternative and Complementary Medicine</i> , 2009 , 15, 507-11	2.4	26
37	Retinal vessel analysis in hypercholesterolemic patients before and after LDL apheresis. <i>Atherosclerosis Supplements</i> , 2009 , 10, 39-43	1.7	31
36	Pharmacokinetic/pharmacodynamic modelling of venlafaxine: pupillary light reflex as a test system for noradrenergic effects. <i>Clinical Pharmacokinetics</i> , 2008 , 47, 721-31	6.2	11
35	Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis. <i>Health and Quality of Life Outcomes</i> , 2008 , 6, 67	3	53
34	Brain-immune communication psychoneuroimmunology of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 6-21	5	30

33	Moderne Immuntherapie der multiplen Sklerose. <i>Aktuelle Neurologie</i> , 2008 , 35, 160-168		0
32	Influence of ECG sampling frequency on spectral analysis of RR intervals and baroreflex sensitivity using the EUROBAVAR data set. <i>Journal of Clinical Monitoring and Computing</i> , 2008 , 22, 159-68	2	52
31	Baroreflex sensitivity and power spectral analysis in different extrapyramidal syndromes. <i>Journal of Neural Transmission</i> , 2008 , 115, 1527-36	4.3	36
30	What can we learn from failed clinical trials in multiple sclerosis?. <i>Journal of Neurology</i> , 2008 , 255 Suppl 6, 97-101	5.5	1
29	Autonomic dysfunction in different subtypes of multiple system atrophy. <i>Movement Disorders</i> , 2008 , 23, 1766-72	7	30
28	Autonomic dysfunction in patients with progressive supranuclear palsy. <i>Movement Disorders</i> , 2008 , 23, 2083-9	7	26
27	Pupil diameter in darkness differentiates progressive supranuclear palsy (PSP) from other extrapyramidal syndromes. <i>Movement Disorders</i> , 2007 , 22, 2123-6	7	21
26	Intravitreal bevacizumab and blood pressure: does it really work? <i>Acta Ophthalmologica</i> , 2007 , 85, 573-4; author reply 574-5		2
25	Glatiramer acetate: mechanisms of action in multiple sclerosis. <i>Autoimmunity Reviews</i> , 2007 , 6, 469-75	13.6	100
24	A new line immunoassay for the multiparametric detection of antiganglioside autoantibodies in patients with autoimmune peripheral neuropathies. <i>Annals of the New York Academy of Sciences</i> , 2007 , 1109, 256-64	6.5	28
23	The effects of lorazepam on skin conductance responses to aversive stimuli in healthy subjects. <i>Clinical Autonomic Research</i> , 2007 , 17, 160-4	4.3	12
22	Psychoneuroimmunology--cross-talk between the immune and nervous systems. <i>Journal of Neurology</i> , 2007 , 254 Suppl 2, I18-11	5.5	51
21	The effects of venlafaxine on autonomic functions in healthy volunteers. <i>Journal of Clinical Psychopharmacology</i> , 2007 , 27, 687-91	1.7	28
20	Non-motor dysfunction in Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2007 , 13, 323-32	3.6	147
19	Stroke-induced immunodepression: experimental evidence and clinical relevance. <i>Stroke</i> , 2007 , 38, 770-7	3.7	354
18	Glatiramer acetate: mechanisms of action in multiple sclerosis. <i>International Review of Neurobiology</i> , 2007 , 79, 537-70	4.4	62
17	Untersuchung zur Genauigkeit der Abtastung von EKG-Signalen für eine nachfolgende Spektralanalyse kontinuierlich gemessener RR-Intervalle im Schlaflabor. <i>Somnologie</i> , 2006 , 10, 53-60	2	3
16	Autonome Dysfunktion beim idiopathischen Parkinson-Syndrom und der Multisystematrophie. <i>Aktuelle Neurologie</i> , 2006 , 33, 385-393		10

15	Multiple sclerosis and the autonomic nervous system. <i>Journal of Neurology</i> , 2006 , 253 Suppl 1, I21-5	5.5	23
14	Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: Implications for multiple sclerosis therapy. <i>Journal of the Neurological Sciences</i> , 2005 , 233, 109-12	3.2	47
13	The role of the humoral immune system in multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE). <i>Autoimmunity Reviews</i> , 2005 , 4, 460-7	13.6	69
12	Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis. <i>Journal of Neurology</i> , 2005 , 252 Suppl 5, v38-45	5.5	15
11	Autoimmune CD4+ T cell memory: lifelong persistence of encephalitogenic T cell clones in healthy immune repertoires. <i>Journal of Immunology</i> , 2005 , 175, 69-81	5.3	40
10	The activation status of neuroantigen-specific T cells in the target organ determines the clinical outcome of autoimmune encephalomyelitis. <i>Journal of Experimental Medicine</i> , 2004 , 199, 185-97	16.6	141
9	Neuroprotection and glatiramer acetate: the possible role in the treatment of multiple sclerosis. <i>Advances in Experimental Medicine and Biology</i> , 2004 , 541, 111-34	3.6	10
8	Adult polyglucosan body disease: a postmortem correlation study. <i>Neurology</i> , 2003 , 61, 263-5	6.5	31
7	Phospholipase A2 degradation products modulate epithelial and stromal 5alpha-reductase activity of human benign prostatic hyperplasia in vitro. <i>Prostate</i> , 2002 , 50, 4-14	4.2	3
6	Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. <i>Brain</i> , 2002 , 125, 2381-91	11.2	199
5	Risk-benefit assessment of glatiramer acetate in multiple sclerosis. <i>Drug Safety</i> , 2001 , 24, 979-90	5.1	56
4	In vitro modulation of steroid 5alpha-reductase activity by phospholipases in epithelium and stroma of human benign prostatic hyperplasia. <i>Steroids</i> , 2001 , 66, 521-8	2.8	4
3	Posttranslationale Regulationsmöglichkeiten membrangebundener Enzyme am Beispiel der prostatichen 5-Reduktase. <i>Laboratoriums Medizin</i> , 1999 , 23, 723-724		
2	The Multiple Sclerosis Health Resource Utilization Survey (MS-HRS): Development and Validation Study (Preprint)		1
1	Targeting Lyn Kinase in Chorea-Acanthocytosis: A Translational Treatment Approach in an Ultra-Rare Disease		1